ASGCT Podcast Network

Leah Myers, Executive Director of the FamilieSCN2A Foundation, and Jenny Burke, who sits on the organization's board, talk about the importance of empowering patients and families affected by genetic diseases. Host: Lynnea OlivarezShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Dr. Charles Murry, a medical doctor and leading researcher in stem cell therapy and organ regeneration, shares insights from his groundbreaking work on reprogramming injured heart cells. He envisions a future where organ regeneration could revolutionize treatments for heart failure and kidney disease. Dr. Murry discusses the shift from industry to academia in cell therapy, emphasizing the need for collaboration in research. Tune in to explore his exciting vision for the next decade in expanding stem cell therapies.

"Storytelling is completely underrated in science," says Benjamin McLeod, a lab scientist-turned-communicator. Listen to him talk about the importance of presenting CGT research in a narrative format. Host: Lynnea OlivarezShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

David Segal, PhD, an abstract session co-chair at the ASGCT Annual Meeting, sheds light on groundbreaking advancements in gene targeting and correction. He discusses the transition of academic innovations like CRISPR from labs to industry, aiming to benefit rare disease patients. Segal highlights the growing influence of biotech in genetic therapies and the crucial challenges of effective delivery systems. The conversation also addresses the FDA's impactful approval of the first gene editing therapy, signaling exciting times ahead for genetic medicine.

ASGCT President Dr. Jeff Chamberlain cuts the ribbon at the ASGCT 27th Annual Meeting and, having planned much of this year's event, reflects on nearly three decades of ASGCT. Host: Lynnea Olivarez, ASGCT Communications CommitteeShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Lynnea Olivarez, incoming ASGCT Communications Committee chair, will be live at the ASGCT 27th Annual Meeting talking to Society leaders, speakers, and abstract presenters about their contributions and what they're excited about at the Annual Meeting. These bite-sized pods are perfect for your walk between the hotel and convention center or your commute to work during the Annual Meeting.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join host Chris Leidli as he sits down with Emily Walsh Martin, PhD, and Lynnea Olivarez to preview the most intriguing and promising abstracts presented at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting in Baltimore. Emily and Lynnea share their thoughts on the breathtaking Presidential Symposium before discussing the rest of the program, including clinical implications, the potential impact on rare diseases, and more! Looking for a curated guide through the Annual Meeting? Check out ASGCT's new Session Paths! These six staff-crafted programs provide pathways for some of the most common Annual Meeting attendee profiles: First-time Attendees Cancer Clinical Science Gene Editing Regulatory + Government Affairs Viral Vectors There's still time to register! Join us at the Annual Meeting in Baltimore or from the comfort of your own home with hybrid registration options! Visit https://annualmeeting.asgct.org/register to learn more and register today.Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Tune in for an exceptional discussion on chemistry, manufacturing, and controls with Dr. Susan D’Costa, Chief Technical and Commercial Officer at Genezen, a US-based CDMO for viral vectors. "Geek out" with Susan and Emily on the intricacies of defining your CMC strategy and ready yourselves for a tour-de-force of analytical and process development for viral vectors. The future of cell and gene therapy is nearly here! The ASGCT Annual Meeting is less than a month away, and starting on April 22, you can download the abstracts collection to get a sneak peek at the cutting-edge research being presented May 7-11 in Baltimore. Explore the latest breakthroughs and discoveries shaping the field, and don't miss the premier event in cell and gene therapy. Visit www.annualmeeting.asgct.org to learn more and register today! Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join Drs. Timothy Cripe and Marco Davila as they discuss a recent article published in the December issue of Molecular Therapy Oncology by Dr. Davila and colleagues titled, Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Dr. Timothy Cripe: Editor-in-Chief of Molecular Therapy Oncology and Professor and Chief of Hematology/Oncology/BMT at Nationwide Children’s Hospital Dr. Marco Davila, Rustum Family Endowed Chair in Translational Research, Senior Vice President and Associate Director for Translational Research, Department of Medicine and Immunology, Roswell Park Comprehensive Cancer Center Host: Dr. Rory Bricker-Anthony, Scientific Editor of the Molecular Therapy Family of Journals ASGCT members save $385 on registration rates for the ASGCT Annual Meeting whether you’re attending in person or virtually! Bundle both ASGCT membership and Annual Meeting attendance and save big on attending the premier event in the field. Register today at annualmeeting.asgct.org. 'Electric Dreams' by Scott Buckley - released under CC-BY 4.0.www.scottbuckley.com.auShow your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.

Join Emily Walsh Martin, PhD for an in-depth interview with Sabrina Mogle, co-founder of RareMoon Consulting. They talk about what drove her to dedicate her career to the orphan drug and advanced therapy space, and how helping clients navigate regulatory conversations on the path from idea to BLA keeps her motivated today. They also discuss her advice for clients in interacting with regulators given the evolving CBER and global regulatory landscape. Do they make it through the whole episode without either providing the standard regulatory wisdom of  “it depends”? Listen to find out! Have you registered for the ASGCT Annual Meeting yet? Meet us in Baltimore, May 7-11, for the only must-attend event in cell and gene therapy. There’s no better place to deep dive in this field than the ASGCT Annual Meeting—you will not find the same breadth or depth of CGT research anywhere in the world. Check out the full program and learn more about the meeting at www.annualmeeting.asgct.org. Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.